System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Practice Guideline Epublish 306 citations

PubMed: 37824423 DOI: 10.15585/mmwr.mm7241e1

Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.

MMWR Morb Mortal Wkly Rep 72(41):1115-1122

Authors: Katherine E Fleming-Dutra, Jefferson M Jones, Lauren E Roper, Mila M Prill, Ismael R Ortega-Sanchez, Danielle L Moulia, Megan Wallace, Monica Godfrey, Karen R Broder, Naomi K Tepper, Oliver Brooks, Pablo J Sánchez, Camille N Kotton, Barbara E Mahon, Sarah S Long, Meredith L McMorrow

Abstract

Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant persons as a single dose during 32-36 completed gestational weeks (i.e., 32 weeks and zero days' through 36 weeks and 6 days' gestation) to prevent RSV-associated lower respiratory tract disease in infants aged <6 months. Since October 2021, CDC's Advisory Committee on Immunization Practices (ACIP) RSV Vaccines Pediatric/Maternal Work Group has reviewed RSV epidemiology and evidence regarding safety, efficacy, and potential economic impact of pediatric and maternal RSV prevention products, including RSVpreF vaccine. On September 22, 2023, ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32-36 weeks' gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.

MeSH

Respiratory Syncytial Viruses, Pregnancy, Mortality, Immunization, Vaccines, Respiratory Tract Diseases, Aged, Viruses, Satellite Viruses, Morbidity, Respiratory Syncytial Virus Vaccines, Infant

Cited by